IPOSchedule
EN
EnglishDeutschFrançais
2026 offering

NODTHERA IPO

NODTHERA develops oral inhibitors of NLRP3.

  • RZRA
  • Nasdaq
  • United States
  • Healthcare
Filed 21 Oct 2026

Offering in progress. A listing date has not been announced, and proposed terms may change.

Last verified 22 Oct 2026

Company overview

NODTHERA website

NODTHERA is a clinical-stage biotechnology company. It is developing a portfolio of internally invented, proprietary and wholly owned oral inhibitors of NLRP3.

Company country
United States

Offering details

USD · Base offering, before overallotment

Exchange
Nasdaq
Ticker
RZRA

IPO timeline

  1. Registration filed

Filings and documents

Other IPO profiles

Industrials01

VME Companies

VME Companies provides engineering, procurement and construction services and modular process systems and equipment.

IPO valuation$276M – $345M
Filings Nasdaq Capital MarketIPO
Industrials02

Helio Corp /FL/

Helio Corporation is a holding company providing technology, engineering, and research and development services.

Listing valuation$29.5M – $36.8M
Filings Nasdaq Capital MarketUplisting
Healthcare03

Neuro Spectrum Insights

Neuro Spectrum Insights develops software to support autism diagnosis through MRI image analysis.

IPO valuation$60.4M – $75.4M
Filings NYSE AmericanIPO